Indian government cracks down on 18 drug companies for poor quality manufacturing
BMJ 2023; 381 doi: https://doi.org/10.1136/bmj.p785 (Published 04 April 2023) Cite this as: BMJ 2023;381:p785- Kamala Thiagarajan
- Madurai, Tamil Nadu, India
The Indian government has cancelled the licences of 18 pharmaceutical companies as part of a crackdown on poor quality manufacturing, it has been reported.1
The action on 29 March came after an inspection of 76 drug firms across 20 Indian states. The government is also understood to have given notices to a further 26 companies for not complying with good manufacturing processes.
The Indian pharmaceutical industry has an estimated 10 500 companies, with drug exports having more than doubled in the past decade. But the industry has faced a series of scandals of late, including a World Health Organization investigation into four contaminated cough syrups that caused acute kidney injuries and were linked to the deaths of 66 children in the Republic of the Gambia last year.2
More recently, WHO sounded the alert in February …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.